BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 24480823)

  • 1. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
    Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
    Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF1
    Dodd RD; Lee CL; Overton T; Huang W; Eward WC; Luo L; Ma Y; Ingram DR; Torres KE; Cardona DM; Lazar AJ; Kirsch DG
    Cancer Res; 2017 Aug; 77(16):4486-4497. PubMed ID: 28646022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural alteration of lung parenchyma in patients with NF1: a phenotyping study using multidetector computed tomography (MDCT).
    Avanesov M; Well L; Laqmani A; Derlin T; Riccardi VM; Adam G; Mautner VF; Salamon J
    Orphanet J Rare Dis; 2021 Jan; 16(1):29. PubMed ID: 33446201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.
    Wojtkowiak JW; Fouad F; LaLonde DT; Kleinman MD; Gibbs RA; Reiners JJ; Borch RF; Mattingly RR
    J Pharmacol Exp Ther; 2008 Jul; 326(1):1-11. PubMed ID: 18367665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical management of craniospinal axis malignant peripheral nerve sheath tumors: a single-institution experience and literature review.
    Chowdhury A; Vivanco-Suarez J; Teferi N; Belzer A; Al-Kaylani H; Challa M; Lee S; Buatti JM; Hitchon P
    World J Surg Oncol; 2023 Oct; 21(1):338. PubMed ID: 37880773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
    Larsson AT; Bhatia H; Calizo A; Pollard K; Zhang X; Conniff E; Tibbitts JF; Rono E; Cummins K; Osum SH; Williams KB; Crampton AL; Jubenville T; Schefer D; Yang K; Lyu Y; Pino JC; Bade J; Gross JM; Lisok A; Dehner CA; Chrisinger JSA; He K; Gosline SJC; Pratilas CA; Largaespada DA; Wood DK; Hirbe AC
    Neuro Oncol; 2023 Nov; 25(11):2044-2057. PubMed ID: 37246765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of treatment sequence and outcomes in patients with relapsed malignant peripheral nerve sheath tumors.
    Zhang L; Lemberg KM; Calizo A; Varadhan R; Siegel AH; Meyer CF; Blakeley JO; Pratilas CA
    Neurooncol Adv; 2023; 5(1):vdad156. PubMed ID: 38130899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Gastrointestinal Stromal Tumors, Malignant Peripheral Nerve Sheath Tumor and Atypical Neurofibromatous Neoplasm With Uncertain Biologic Potential Developing in A Single Patient With Neurofibromatosis Type 1 Syndrome.
    Cerrah E; Çomunoğlu C
    Int J Surg Pathol; 2024 Feb; ():10668969241229350. PubMed ID: 38303154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.
    Lemberg KM; Zhao L; Wu Y; Veeravalli V; Alt J; Aguilar JMH; Dash RP; Lam J; Tenora L; Rodriguez C; Nedelcovych MT; Brayton C; Majer P; Blakeley JO; Rais R; Slusher BS
    Mol Cancer Ther; 2020 Feb; 19(2):397-408. PubMed ID: 31594823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.
    Godec A; Jayasinghe R; Chrisinger JSA; Prudner B; Ball T; Wang Y; Srihari D; Kaushal M; Dietz H; Zhang X; Pekmezci M; Dahiya S; Tao Y; Luo J; Van Tine BA; Ding L; Gutmann DH; Hirbe AC
    Neurooncol Adv; 2020 Jul; 2(Suppl 1):i75-i84. PubMed ID: 32642734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.
    Evans DG; O'Hara C; Wilding A; Ingham SL; Howard E; Dawson J; Moran A; Scott-Kitching V; Holt F; Huson SM
    Eur J Hum Genet; 2011 Nov; 19(11):1187-91. PubMed ID: 21694737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis.
    Lim Z; Gu TY; Tai BC; Puhaindran ME
    World J Surg Oncol; 2024 Jan; 22(1):14. PubMed ID: 38191386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant peripheral nerve sheath tumors: prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1 status and location.
    Kamran SC; Howard SA; Shinagare AB; Krajewski KM; Jagannathan JP; Hornick JL; Ramaiya NH
    Eur J Surg Oncol; 2013 Jan; 39(1):46-52. PubMed ID: 23084090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy.
    Moretti VM; Crawford EA; Staddon AP; Lackman RD; Ogilvie CM
    Am J Clin Oncol; 2011 Aug; 34(4):417-21. PubMed ID: 20838322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).
    Valentin T; Le Cesne A; Ray-Coquard I; Italiano A; Decanter G; Bompas E; Isambert N; Thariat J; Linassier C; Bertucci F; Bay JO; Bellesoeur A; Penel N; Le Guellec S; Filleron T; Chevreau C
    Eur J Cancer; 2016 Mar; 56():77-84. PubMed ID: 26824706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.
    Ziadi A; Saliba I
    Auris Nasus Larynx; 2010 Oct; 37(5):539-45. PubMed ID: 20399579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
    Kolberg M; Høland M; Agesen TH; Brekke HR; Liestøl K; Hall KS; Mertens F; Picci P; Smeland S; Lothe RA
    Neuro Oncol; 2013 Feb; 15(2):135-47. PubMed ID: 23161774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.
    Lamm W; Schur S; Köstler WJ; Funovics P; Windhager R; Amann G; Panotopoulos J; Pokrajac B; Brodowicz T
    Oncology; 2014; 86(2):122-6. PubMed ID: 24480823
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.